FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004646918> ?p ?o ?g. }

• W2004646918 endingPage "1704" @default.
• W2004646918 startingPage "1697" @default.
• W2004646918 abstract "Natalizumab, a therapy for multiple sclerosis (MS), has been associated with progressive multifocal leukoencephalopathy (PML), a rare opportunistic infection of the CNS associated with the JC virus. We assessed clinical outcomes and identified variables associated with survival in 35 patients with natalizumab-associated PML.Physicians provided Karnofsky scores and narrative descriptions of clinical status. Data were supplemented by the natalizumab global safety database.At the time of analysis, 25 patients (71%) had survived. Survivors were younger (median 40 vs 54 years) and had lower pre-PML Expanded Disability Status Scale scores (median 3.5 vs 5.5) and a shorter time from symptom onset to diagnosis (mean 44 vs 63 days) compared with individuals with fatal cases. Of patients with nonfatal cases, 86% had unilobar or multilobar disease on brain MRI at diagnosis, whereas 70% of those with fatal cases had widespread disease. Gender, MS duration, natalizumab exposure, prior immunosuppressant use, and CSF JC viral load at diagnosis were comparable. Most patients were treated with rapid removal of natalizumab from the circulation. The majority of patients developed immune reconstitution inflammatory syndrome and were treated with corticosteroids. Among survivors with at least 6 months follow-up, disability levels were evenly distributed among mild, moderate, and severe, based on physician-reported Karnofsky scores.Natalizumab-associated PML has improved survival compared with PML in other populations. Disability in survivors ranged from mild to severe. A shorter time from symptom onset to diagnosis and localized disease on MRI at diagnosis were associated with improved survival. These data suggest that earlier diagnosis through enhanced clinical vigilance and aggressive management may improve outcomes." @default.
• W2004646918 created "2016-06-24" @default.
• W2004646918 creator A5015275115 @default.
• W2004646918 creator A5025462803 @default.
• W2004646918 creator A5027116773 @default.
• W2004646918 creator A5028240490 @default.
• W2004646918 creator A5054874316 @default.
• W2004646918 creator A5062220148 @default.
• W2004646918 creator A5083890663 @default.
• W2004646918 creator A5088163706 @default.
• W2004646918 date "2011-05-16" @default.
• W2004646918 modified "2023-09-30" @default.
• W2004646918 title "Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy" @default.
• W2004646918 cites W1904205969 @default.
• W2004646918 cites W1970547229 @default.
• W2004646918 cites W1978994973 @default.
• W2004646918 cites W2000379621 @default.
• W2004646918 cites W2010643375 @default.
• W2004646918 cites W2036909473 @default.
• W2004646918 cites W2038756078 @default.
• W2004646918 cites W2071917362 @default.
• W2004646918 cites W2078765085 @default.
• W2004646918 cites W2081889592 @default.
• W2004646918 cites W2087950157 @default.
• W2004646918 cites W2095390622 @default.
• W2004646918 cites W2106747769 @default.
• W2004646918 cites W2130730608 @default.
• W2004646918 cites W2139131948 @default.
• W2004646918 cites W2142331234 @default.
• W2004646918 cites W2145068137 @default.
• W2004646918 cites W2155620154 @default.
• W2004646918 cites W2159061752 @default.
• W2004646918 cites W2165229568 @default.
• W2004646918 cites W2166282475 @default.
• W2004646918 cites W2169077473 @default.
• W2004646918 cites W2169573102 @default.
• W2004646918 cites W2169726349 @default.
• W2004646918 cites W2278220001 @default.
• W2004646918 cites W2333042560 @default.
• W2004646918 cites W3146270511 @default.
• W2004646918 cites W99446109 @default.
• W2004646918 doi "https://doi.org/10.1212/wnl.0b013e31821a446b" @default.
• W2004646918 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21576685" @default.
• W2004646918 hasPublicationYear "2011" @default.
• W2004646918 type Work @default.
• W2004646918 sameAs 2004646918 @default.
• W2004646918 citedByCount "176" @default.
• W2004646918 countsByYear W20046469182012 @default.
• W2004646918 countsByYear W20046469182013 @default.
• W2004646918 countsByYear W20046469182014 @default.
• W2004646918 countsByYear W20046469182015 @default.
• W2004646918 countsByYear W20046469182016 @default.
• W2004646918 countsByYear W20046469182017 @default.
• W2004646918 countsByYear W20046469182018 @default.
• W2004646918 countsByYear W20046469182019 @default.
• W2004646918 countsByYear W20046469182020 @default.
• W2004646918 countsByYear W20046469182021 @default.
• W2004646918 countsByYear W20046469182022 @default.
• W2004646918 countsByYear W20046469182023 @default.
• W2004646918 crossrefType "journal-article" @default.
• W2004646918 hasAuthorship W2004646918A5015275115 @default.
• W2004646918 hasAuthorship W2004646918A5025462803 @default.
• W2004646918 hasAuthorship W2004646918A5027116773 @default.
• W2004646918 hasAuthorship W2004646918A5028240490 @default.
• W2004646918 hasAuthorship W2004646918A5054874316 @default.
• W2004646918 hasAuthorship W2004646918A5062220148 @default.
• W2004646918 hasAuthorship W2004646918A5083890663 @default.
• W2004646918 hasAuthorship W2004646918A5088163706 @default.
• W2004646918 hasConcept C126322002 @default.
• W2004646918 hasConcept C142462285 @default.
• W2004646918 hasConcept C187212893 @default.
• W2004646918 hasConcept C203014093 @default.
• W2004646918 hasConcept C2522874641 @default.
• W2004646918 hasConcept C2778583010 @default.
• W2004646918 hasConcept C2779134260 @default.
• W2004646918 hasConcept C2779150272 @default.
• W2004646918 hasConcept C2779778235 @default.
• W2004646918 hasConcept C2780640218 @default.
• W2004646918 hasConcept C2780644213 @default.
• W2004646918 hasConcept C2780892749 @default.
• W2004646918 hasConcept C2781004633 @default.
• W2004646918 hasConcept C2993143319 @default.
• W2004646918 hasConcept C71924100 @default.
• W2004646918 hasConceptScore W2004646918C126322002 @default.
• W2004646918 hasConceptScore W2004646918C142462285 @default.
• W2004646918 hasConceptScore W2004646918C187212893 @default.
• W2004646918 hasConceptScore W2004646918C203014093 @default.
• W2004646918 hasConceptScore W2004646918C2522874641 @default.
• W2004646918 hasConceptScore W2004646918C2778583010 @default.
• W2004646918 hasConceptScore W2004646918C2779134260 @default.
• W2004646918 hasConceptScore W2004646918C2779150272 @default.
• W2004646918 hasConceptScore W2004646918C2779778235 @default.
• W2004646918 hasConceptScore W2004646918C2780640218 @default.
• W2004646918 hasConceptScore W2004646918C2780644213 @default.
• W2004646918 hasConceptScore W2004646918C2780892749 @default.
• W2004646918 hasConceptScore W2004646918C2781004633 @default.
• W2004646918 hasConceptScore W2004646918C2993143319 @default.
• W2004646918 hasConceptScore W2004646918C71924100 @default.

• next